Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Get Started for Free
Brian Cheng is an analyst at JP Morgan. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 07/24/2024
| Buy Now | Get Alert | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 07/25/2024 | PTGX | Buy Now | Protagonist Therapeutics | $42.99 | 11.65% | $39 → $48 | Maintains | Overweight | Get Alert |
| 05/02/2024 | MGX | Buy Now | Metagenomi | $4.40 | 36.36% | $16 → $6 | Downgrade | Overweight → Neutral | Get Alert |
| 04/30/2024 | IMNM | Buy Now | Immunome | $15.24 | 57.48% | → $24 | Initiates | → Overweight | Get Alert |
| 03/22/2024 | PGEN | Buy Now | Precigen | $1.67 | — | — | Downgrade | Neutral → Underweight | Get Alert |
| 03/19/2024 | MRSN | Buy Now | Mersana Therapeutics | $2.13 | 134.74% | → $5 | Upgrade | Underweight → Neutral | Get Alert |
| 03/12/2024 | ITOS | Buy Now | ITeos Therapeutics | $16.41 | 64.53% | $29 → $27 | Maintains | Overweight | Get Alert |
| 03/05/2024 | MGX | Buy Now | Metagenomi | $4.40 | 263.64% | → $16 | Initiates | → Overweight | Get Alert |
| 03/04/2024 | AHR | Buy Now | American Healthcares | $16.45 | -8.81% | → $15 | Initiates | → Outperform | Get Alert |
| 03/04/2024 | KYTX | Buy Now | Kyverna Therapeutics | $8.92 | 337.22% | → $39 | Initiates | → Overweight | Get Alert |
| 02/28/2024 | PTGX | Buy Now | Protagonist Therapeutics | $42.99 | -13.93% | $34 → $37 | Maintains | Overweight | Get Alert |
| 02/27/2024 | ALLO | Buy Now | Allogene Therapeutics | $2.89 | 176.42% | $9 → $8 | Maintains | Overweight | Get Alert |
| 02/27/2024 | EDIT | Buy Now | Editas Medicine | $5.32 | 69.17% | $8 → $9 | Maintains | Neutral | Get Alert |
| 02/20/2024 | IMVT | Buy Now | Immunovant | $28.23 | 80.66% | → $51 | Initiates | → Overweight | Get Alert |
| 12/05/2023 | CRGX | Buy Now | Cargo Therapeutics | $17.34 | 32.64% | → $23 | Initiates | → Overweight | Get Alert |
| 11/14/2023 | ROIV | Buy Now | Roivant Sciences | $10.81 | 38.76% | $16 → $15 | Maintains | Overweight | Get Alert |
| 10/18/2023 | EDIT | Buy Now | Editas Medicine | $5.32 | 50.38% | → $8 | Upgrade | Underweight → Neutral | Get Alert |
| 10/12/2023 | APLS | Buy Now | Apellis Pharmaceuticals | $39.25 | 17.2% | $44 → $46 | Maintains | Neutral | Get Alert |
| 09/25/2023 | PTGX | Buy Now | Protagonist Therapeutics | $42.99 | -20.91% | $36 → $34 | Maintains | Overweight | Get Alert |
| 09/25/2023 | BCAB | Buy Now | BioAtla | $1.70 | 723.38% | $17 → $14 | Maintains | Overweight | Get Alert |
| 09/25/2023 | ALLO | Buy Now | Allogene Therapeutics | $2.89 | 210.98% | $11 → $9 | Maintains | Overweight | Get Alert |
| 09/08/2023 | APLS | Buy Now | Apellis Pharmaceuticals | $39.25 | 9.55% | $40 → $43 | Maintains | Neutral | Get Alert |
| 08/10/2023 | ADCT | Buy Now | ADC Therapeutics | $3.97 | — | — | Upgrade | Underweight → Neutral | Get Alert |
| 08/02/2023 | BCAB | Buy Now | BioAtla | $1.70 | 899.82% | $19 → $17 | Maintains | Overweight | Get Alert |
| 08/01/2023 | APLS | Buy Now | Apellis Pharmaceuticals | $39.25 | 1.91% | $114 → $40 | Downgrade | Buy → Neutral | Get Alert |
| 06/16/2023 | MRSN | Buy Now | Mersana Therapeutics | $2.13 | 134.74% | $11 → $5 | Downgrade | Overweight → Neutral | Get Alert |
| 06/01/2023 | ACET | Buy Now | Adicet Bio | $1.43 | 319.43% | $20 → $6 | Downgrade | Overweight → Neutral | Get Alert |
| 05/23/2023 | PGEN | Buy Now | Precigen | $1.67 | — | — | Initiates | → Neutral | Get Alert |
| 05/18/2023 | ROIV | Buy Now | Roivant Sciences | $10.81 | 29.51% | $12 → $14 | Maintains | Overweight | Get Alert |
| 04/03/2023 | BCAB | Buy Now | BioAtla | $1.70 | 1017.45% | $23 → $19 | Maintains | Overweight | Get Alert |
| 03/31/2023 | NTLA | Buy Now | Intellia Therapeutics | $26.43 | 198.85% | $82 → $79 | Maintains | Overweight | Get Alert |
| 03/31/2023 | ZYME | Buy Now | Zymeworks | $10.40 | -13.46% | $8 → $9 | Maintains | Neutral | Get Alert |
| 03/29/2023 | ROIV | Buy Now | Roivant Sciences | $10.81 | 11.01% | → $12 | Maintains | Overweight | Get Alert |
| 03/16/2023 | MRSN | Buy Now | Mersana Therapeutics | $2.13 | 369.48% | → $10 | Upgrade | Neutral → Overweight | Get Alert |
| 02/13/2023 | XNCR | Buy Now | Xencor | $20.41 | 105.78% | $37 → $42 | Maintains | Overweight | Get Alert |
| 02/13/2023 | ROIV | Buy Now | Roivant Sciences | $10.81 | 1.76% | $10 → $11 | Maintains | Overweight | Get Alert |
| 01/24/2023 | ALLO | Buy Now | Allogene Therapeutics | $2.89 | 280.08% | $20 → $11 | Upgrade | Neutral → Overweight | Get Alert |
| 01/10/2023 | ROIV | Buy Now | Roivant Sciences | $10.81 | -7.49% | $9 → $10 | Maintains | Overweight | Get Alert |
| 12/16/2022 | SNTI | Buy Now | Senti Biosciences | $2.40 | — | — | Initiates | → Neutral | Get Alert |
| 12/12/2022 | ROIV | Buy Now | Roivant Sciences | $10.81 | -16.74% | → $9 | Maintains | Overweight | Get Alert |
| 12/07/2022 | GOSS | Buy Now | Gossamer Bio | $1.09 | — | — | Downgrade | Neutral → Underweight | Get Alert |
| 11/10/2022 | CLVS | Buy Now | Clovis Oncology | — | — | — | Downgrade | Neutral → Underweight | Get Alert |
| 09/21/2022 | NTLA | Buy Now | Intellia Therapeutics | $26.43 | 221.54% | → $85 | Initiates | → Overweight | Get Alert |
| 09/21/2022 | ACET | Buy Now | Adicet Bio | $1.43 | 1507.83% | → $23 | Initiates | → Overweight | Get Alert |
| 09/21/2022 | XNCR | Buy Now | Xencor | $20.41 | 81.28% | → $37 | Initiates | → Overweight | Get Alert |
| 09/21/2022 | ADCT | Buy Now | ADC Therapeutics | $3.97 | 26.04% | → $5 | Initiates | → Overweight | Get Alert |
| 09/21/2022 | GOSS | Buy Now | Gossamer Bio | $1.09 | 1459.63% | → $17 | Initiates | → Neutral | Get Alert |
| 01/07/2022 | PSTX | Buy Now | Poseida Therapeutics | $3.34 | 618.56% | → $24 | Initiates | → Overweight | Get Alert |
| 11/30/2021 | SRRA | Buy Now | Sierra Oncology | — | — | — | Maintains | Overweight | Get Alert |
